吉西他滨联合S-1或优福定治疗晚期胰腺癌患者
[Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
作者信息
Sasajima Junpei, Tanno Satoshi, Koizumi Kazuya, Nakano Yasuhiro, Habiro Atsuya, Chiba Atsushi, Fujii Tsuneshi, Sugiyama Yoshiaki, Nakamura Kazumasa, Nishikawa Tomoya, Mizukami Yusuke, Okumura Toshikatsu, Kohgo Yutaka
机构信息
Dept. of Gastroenterology and Hematology/Oncology, Asahikawa Medical College.
出版信息
Gan To Kagaku Ryoho. 2009 Oct;36(10):1657-61.
The present retrospective study aimed to evaluate the anti-tumor activity and toxicity of combination chemotherapy with gemcitabine (GEM) and oral S-1 or UFT in patients with advanced or metastatic pancreatic cancer. Ninety-four patients received chemotherapy. Among them, sixty-three were treated with GEM alone, twenty-two with UFT and GEM (UFT/GEM), and nine with S-1 and GEM(S-1/GEM). The median survival time was 8.7 months with GEM, 7.3 months with UFT/GEM, and 23.3 months with S-1/GEM. The overall response rate was 11.1%, 10.0%, and 22.2%, respectively. The 1-year survival rate was 29.5%, 36.4%, and 85.7%, respectively. Although the treatment-related adverse effects were not infrequent in patients treated with S-1/GEM, they were moderate in intensity. The combination chemotherapy with S-1/GEM was well tolerated and yielded a high response rate in patients with pancreatic cancer.
本回顾性研究旨在评估吉西他滨（GEM）联合口服S-1或优福定对晚期或转移性胰腺癌患者的抗肿瘤活性及毒性。94例患者接受了化疗。其中，63例单独接受吉西他滨治疗，22例接受优福定与吉西他滨联合治疗（优福定/吉西他滨），9例接受S-1与吉西他滨联合治疗（S-1/吉西他滨）。吉西他滨治疗组的中位生存时间为8.7个月，优福定/吉西他滨治疗组为7.3个月，S-1/吉西他滨治疗组为23.3个月。总缓解率分别为11.1%、10.0%和22.2%。1年生存率分别为29.5%、36.4%和85.7%。虽然S-1/吉西他滨治疗的患者中与治疗相关的不良反应并不少见，但强度为中度。S-1/吉西他滨联合化疗耐受性良好，在胰腺癌患者中产生了较高的缓解率。
Zotero 插件